Edgar Filing: Stark David Matthew - Form 4

Stark David	Matthew										
Form 4	010										
March 19, 2										PPROVAL	
					SAND EXCHANGE COMMISSION			OMB OMB Number:	3235-0287		
Check this box				Washington, D.C. 20549						January 31,	
if no lon subject t Section Form 4 c	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Expires: 2005 Estimated average burden hours per response 0.5				
Form 5 Filed pursuant to Section 16(a) of the Securities Exchange A Section 17(a) of the Public Utility Holding Company Act of 19 See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange A 30(h) of the Investment Company Act of 1940							f 1935 or Section	·			
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Stark David Matthew			2. Issuer Name and Ticker or Trading Symbol TEVA PHARMACEUTICAL				-	5. Relationship of Reporting Person(s) to Issuer			
			INDUSTRIES LTD [TEVA]					(Check all applicable)			
(Last) (First) (Middle) C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 5 BASEL			3. Date of Earliest Transaction(Month/Day/Year)03/17/2019					Director 10% Owner X Officer (give title Other (specify below) below) Exec. VP Chief Legal Officer			
STREET	LS LID., 5 DA	JEL									
	(Street)		4. If Ame Filed(Mor	Date Original ar)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
PETACH T	TIKVA, L3 4951	033						Form filed by M Person	fore than One Re	porting	
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	rities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Dee (Month/Day/Year) Execution any (Month/			4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5) (A)			Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
				Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Ordinary Shares (1)	03/17/2019			М	2,358	А	<u>(2)</u>	5,332.39	D		
Ordinary Shares ⁽¹⁾	03/18/2019			S <u>(3)</u>	2,358	D	\$ 16.43	2,974.39	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Stark David Matthew - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	e 3A. Deemed Execution Date, if any (Month/Day/Year)	Code	5. Number ionof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Pri Deriv Secu (Instr
				Code V	7 (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Share Units	<u>(2)</u>	03/17/2019		М	2,358	(4)	(4)	Ordinary Shares (1)	2,358	\$

Reporting Owners

Reporting Owner Name / Address	Relationships					
FB	Director	10% Owner	Officer	Other		
Stark David Matthew C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 5 BASEL STREET PETACH TIKVA, L3 4951033			Exec. VP Chief Legal Officer			
Signatures						

/s/ Dov Bergwerk, as attorney-in-fact for David M. Stark

**Signature of Reporting Person

03/19/2019 Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- (2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- (3) The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- (4) Restricted share units were granted on March 17, 2016, with 2,358 vesting on each of March 17, 2018 and March 17, 2019 and 2,359 vesting on March 17, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.